Republic of the Philippines
Department of Health
OFFICE OF THE SECRETARY

September 1, 2020

DEPARTMENT CIRCULAR
No. 2020- 0326

TO : **ALL UNDERSECRETARIES; ASSISTANT SECRETARIES; DIRECTORS OF BUREAUS, CENTERS FOR HEALTH DEVELOPMENT AND SERVICES; EXECUTIVE DIRECTORS OF SPECIALTY HOSPITALS, AND NATIONAL NUTRITION COUNCIL; CHIEFS OF MEDICAL CENTERS, HOSPITALS, SANITARIA AND INSTITUTES; PRESIDENT OF THE PHILIPPINE HEALTH INSURANCE CORPORATION; DIRECTORS OF PHILIPPINE NATIONAL AIDS COUNCIL AND TREATMENT AND REHABILITATION CENTERS; AND OTHERS CONCERNED**

SUBJECT : **DIRECTIVE FOR THE CONDUCT OF ALL CLINICAL TRIALS FOR COVID-19**

In order to centralize information and communication on the conduct of clinical trials, the Department of Health (DOH) mandates all principal investigators of all clinical trials for COVID-19 drugs and vaccines to notify DOH and submit relevant information using the attached Clinical Trial Notification Form and weekly updates to the Health Research Division (covid19evid@gmail.com; subject: [Clinical Trial]) of the Health Policy Development and Planning Bureau, and to the Health Regulation Team (hrt.clinicaltrial@gmail.com). Select trial information will be made publicly available through the COVID-19 Local Evidence Database (https://hpdpb.doh.gov.ph/health-research-division /doh-covid-19-evidence-database/).

The Department of Health also reiterates Administrative Order No. 2020-0010 entitled "Regulation on the Conduct of Clinical Trials for Investigational Products," which states the requirements needed for the conduct of clinical trials.

Dissemination of the information to all concerned is requested.

FRANCISCO T. DUQUE III, MD, MSc
Secretary of Health

CLINICAL TRIAL NOTIFICATION FORM

Clinical Trial Information					
Full Title of Clinical Trial					
Principal Investigator /Institution/Email and Mobile Number					
Trial Sponsor/s					
Phase to be conducted	Phase I	Phase II	Phase III	Phase IV	Others (specify) _____
Attachments	• Approval Letter from the FDA • Approval Letter from PHREB-accredited Level 3 REC and Institutional Endorsement Letter • Clinical Trial Protocol and Protocol Amendment/s				
Name of Investigational Product					
Proposed indication and Dosage information					
Target population/ Characteristics of trial subjects					
Total number of subjects in the Philippines					
Expected start date:					
Expected end date					

STUDY SITES (Provide tabulation on a separate sheet if necessary)

Name of Study Site	**Site Investigator**	**Contact Details (Email and Contact Number**